Issue 06 · March 1, 2026 The Switch Stack
The Switch Stack
Where the numbers flip the narrative
#01 #02 #03 #04 #05 #06 #07

The Drug Ledger: Every Number, Every Source

Legal vs. illegal. Deaths vs. policy. The data on what kills, what heals, what we ban, and what we sell.

Annual US Death Toll by Substance
Tobacco Legal
480,000
Alcohol Legal
178,000
All drug overdoses Mixed
105,007
Synth. opioids (fentanyl) Rx+Illicit
72,776
Cocaine Illegal
29,449
Rx opioids Legal (Rx)
14,716
Heroin Illegal
5,871
Cannabis Sched. I
0
Psilocybin Sched. I
0

Sources: CDC, NIDA, NIAAA (2023 data unless noted). Cannabis: zero documented fatal overdoses from direct pharmacological toxicity. 70% of cocaine deaths also involve fentanyl.

The War on Drugs: $1 Trillion in Numbers
$1T+
since 1971
Total federal spending on the War on Drugs
CNBC, White House ONDCP
$41B
per year (2022 est.)
Federal drug control budget. Up from $81M in 1969.
White House ONDCP
1,090%
increase, inflation-adjusted
Drug budget growth from 1981 to 2020
CNBC analysis
44–46%
of federal prisoners
Incarcerated for drug offenses (~89,000 of ~154,000)
BOP, USSC (2024–2025)
361K
people
Total incarcerated for drug offenses across all US facilities
Prison Policy Initiative
105,007
deaths (2023)
Total drug overdose deaths — after 50+ years of the War on Drugs
CDC/NIDA
The Pharmaceutical Pipeline: From Lab to Crisis
1960
Beerse, Belgium
Paul Janssen synthesizes fentanyl at Janssen Pharmaceutica. 50–100x more potent than morphine.
PMC, multiple
$1.1B
annual revenue by year 4
OxyContin (Purdue Pharma, 1996). Sales reps: “Fewer than 1% become addicted.”
PMC2622774
$7.4B
settlement (Dec 2024)
Sackler family: $6.5B / 15 yrs. Purdue: $900M upfront. 0 prison sentences.
DOJ, multiple AG offices
806K
deaths (1999–2023)
Cumulative US opioid overdose deaths. $9,180 settlement per death.
CDC
>$35B
total revenue [APPROXIMATE]
OxyContin lifetime sales. Sacklers extracted >$10B before bankruptcy.
Media reports
72,776
deaths (2023)
Synthetic opioid deaths — primarily illicit fentanyl, Janssen’s molecule.
NIDA
What Works: Decriminalization & Medicalization Data

Portugal (2001–present)

−98.8%

Reduction in HIV diagnoses among people who inject drugs: 1,287 (2001) to 16 (2019)

−87%

Drug deaths at lowest point: 76 (2001) to 10 (2011). Now ~30, still below pre-reform.

Drug death rate: 6/million vs EU average 23.7/million (2019)

Youth drug use: Below EU average for 20+ years

Caveat: Post-2009 austerity eroded treatment funding. Drug deaths rose from 2011 low.

EMCDDA, Transform Drug Policy Foundation

Oregon Measure 110 (2021–2024)

Confounded

Brown University (2024): After controlling for fentanyl, M110 NOT associated with increased overdose deaths.

Passed: Nov 2020 (58.5%). Repealed: Sep 2024.

Treatment funding: $265M allocated (slow rollout)

Violent crime: No increase

Confounders: COVID-19, fentanyl wave, inadequate infrastructure

Honest read: Decriminalization without treatment = insufficient. But did not cause OD deaths.

Brown University, Portland State, OPB

Switzerland Psychedelic Therapy (2024)

723

Patients treated with psychedelics under medical supervision in 2024

Psilocybin: 348 patients · MDMA: 245 · LSD: 130

Physicians authorized: ~100

Total treatments: ~1,660

Since: 2014 (MDMA/LSD), 2021 (psilocybin)

Swiss Federal Office of Public Health, PMC

Netherlands Coffee Shops (1976–present)

50 yrs

Cannabis tolerated in licensed coffee shops since 1976

Cannabis use: At or below comparable European countries

Gateway effect: 14% access other drugs from cannabis source (vs 52% in Sweden)

Youth use: Lower than many stricter countries

HIV among PWID: Low

RAND, Open Society Foundations
Clinical Evidence: Psilocybin vs. SSRI
Measure Psilocybin (n=30) Escitalopram (n=29) Result
QIDS-SR-16 change (6 wk) −8.0 ± 1.0 −6.0 ± 1.0 Not statistically significant (primary)
Remission at 6 weeks 57% Lower* Favored psilocybin (secondary)
Hamilton Depression (HDRS) Significant — Favored psilocybin
Montgomery-Åsberg (MADRS) Significant — Favored psilocybin
Beck Depression (BDI) Significant — Favored psilocybin
6-month follow-up Sustained — Lancet eClinicalMedicine 2024

*Exact escitalopram remission rate not specified in published results. Carhart-Harris et al., NEJM 2021. Caveat: small sample (n=59), secondary outcomes not corrected for multiple comparisons. Promising but not definitive.

The Full Ledger: Substance, Status, Deaths, Schedule
Substance US Legal Status Schedule Annual US Deaths Source
Tobacco Legal (21+) None 480,000 CDC
Alcohol Legal (21+) None 178,000 NIAAA 2020–21
Synth. opioids (fentanyl) Rx + Illicit II 72,776 NIDA 2023
Cocaine Illegal II 29,449 NIDA 2023
Rx opioids Legal (Rx) II–IV 14,716 CDC 2023
Heroin Illegal I 5,871 NIDA 2023
Cannabis Illegal (federal) I 0 CDC/DEA
Psilocybin Illegal I 0 No documented OD
MDMA Illegal I Rare —
The Switch: The three deadliest substances (tobacco, alcohol, Rx opioids) are all legal. The two Schedule I substances with the lowest death tolls (cannabis, psilocybin) are classified as having “no accepted medical use” — despite psilocybin showing clinical evidence of efficacy for depression and cannabis being legal for medical/recreational use in the majority of US states. Cannabis “zero deaths” refers to direct pharmacological overdose; deaths involving cannabis are almost always polydrug (96% in England 1998–2020 data). Every number in this article is traceable to analysis.md.
← Back to Issue 06